Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Ji Hyun Park, Claudio Luchini, Alessia Nottegar, Kalthoum Tizaoui, Ai Koyanagi, Shuji Ogino, Jae Il Shin, Beom Jin Lim & Lee Smith. (2023) Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis. Journal of Clinical Pathology, pages jcp-2023-208848.
Crossref
Crossref
Maria P. Meivita, Denise Lee, J Shamita Naikar, Shao-Xiang Go, Wey Chyi Teoh, Yaw Sing Tan, Natasa Bajalovic & Desmond K. Loke. (2022) An Efficient, Short Stimulus PANC-1 Cancer Cell Ablation and Electrothermal Therapy Driven by Hydrophobic Interactions. Pharmaceutics 15:1, pages 106.
Crossref
Crossref
Lubna O. Abdel-Salam, Hala El Hanbuli & Dalia Nabil Abdelhafez. (2022) Tumoral and Stromal Pdl1 and Pdl2 Checkpoints Immunohistochemical Expression in Pancreatic Ductal Adenocarcinoma, a Promising Field Of Study. Open Access Macedonian Journal of Medical Sciences 10:A, pages 775-781.
Crossref
Crossref
Da-Lai Xu, Yuan-Qing He, Bin Xiao, Yuan Si, Jian Shi, Xue-Ang Liu, Lei Tian, Qian Ren, Ya-Song Wu & Yi Zhu. (2022) A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. Frontiers in Oncology 12.
Crossref
Crossref
Ruizhe Wang, Yi Zhang & Fengping Shan. (2022) PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. International Immunopharmacology 103, pages 108484.
Crossref
Crossref
Michael MuggilliDonna RussellZhongren Zhou. (2021) Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples. Cytojournal 18, pages 28.
Crossref
Crossref
Sun Mi Lee & Chang Ohk Sung. (2021) PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions. Pancreatology 21:5, pages 920-927.
Crossref
Crossref
Justyna Magdalena Hermanowicz, Krystyna Pawlak, Beata Sieklucka, Robert Czarnomysy, Iwona Kwiatkowska, Adam Kazberuk, Arkadiusz Surazynski, Mariusz Mojzych & Dariusz Pawlak. (2021) MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer. Cancers 13:13, pages 3203.
Crossref
Crossref
Kyösti Tahkola, Maarit Ahtiainen, Jukka-Pekka Mecklin, Ilmo Kellokumpu, Johanna Laukkarinen, Markku Tammi, Raija Tammi, Juha P. Väyrynen & Jan Böhm. (2021) Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer. Scientific Reports 11:1.
Crossref
Crossref
Zhiyan Ruan, Minhua Liang, Ling Shang, Manxiang Lai, Xiangliang Deng & Xinguo Su. (2021) Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. Pancreatology 21:3, pages 630-641.
Crossref
Crossref
Kyösti Tahkola, Maarit Ahtiainen, Ilmo Kellokumpu, Jukka-Pekka Mecklin, Johanna Laukkarinen, Joni Laakkonen, Istvan Kenessey, Sirpa Jalkanen, Marko Salmi & Jan Böhm. (2020) Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Archiv 478:2, pages 209-217.
Crossref
Crossref
Masahiro Kikuchi, Daisuke Yamashita, Shigeo Hara, Shinji Takebayashi, Kiyomi Hamaguchi, Keisuke Mizuno, Koichi Omori & Shogo Shinohara. (2020) Clinical significance of tumor‐associated immune cells in patients with oral squamous cell carcinoma. Head & Neck 43:2, pages 534-543.
Crossref
Crossref
Lin Shui, Ke Cheng, Xiaofen Li, Pixian Shui, Xiaohan Zhou, Jian Li, Cheng Yi & Dan Cao. (2020) Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. BMC Cancer 20:1.
Crossref
Crossref
Rumiana Bakalova, Severina Semkova, Donika Ivanova, Zhivko Zhelev, Thomas Miller, Tsuguhide Takeshima, Sayaka Shibata, Dessislava Lazarova, Ichio Aoki & Tatsuya Higashi. (2020) Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant. Oxidative Medicine and Cellular Longevity 2020, pages 1-30.
Crossref
Crossref
J. Spencer Lane, Daniel Von Hoff, Derek Cridebring & Ajay Goel. (2020) Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives. Cancers 12:6, pages 1530.
Crossref
Crossref
Yong-Xin Cui & Xian-Shuang Su. (2020) Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma. Open Medicine 15:1, pages 292-301.
Crossref
Crossref
Jerry B. Harvey, Luan H. Phan, Oscar E. Villarreal & Jessica L. Bowser. (2020) CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Frontiers in Immunology 11.
Crossref
Crossref
Xiaobin Gu, Meilian Dong, Zheyan Liu, Yin Mi, Jing Yang, Zhigang Zhang, Ke Liu, Li Jiang, Yue Zhang, Shiliang Dong & Yonggang Shi. (2019) Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. Cancer Cell International 19:1.
Crossref
Crossref
Wen‐Yang Zhou, Ming‐Ming Zhang, Chang Liu, Ye Kang, Jin‐Ou Wang & Xiang‐Hong Yang. (2019) Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death‐ligand 1 by sponging microRNA‐195‐5p. Journal of Cellular Physiology 234:12, pages 23176-23189.
Crossref
Crossref
Kazuyuki Matsumoto, Toshiaki Ohara, Masayoshi Fujisawa, Akinobu Takaki, Masahiro Takahara, Noriyuki Tanaka, Hironari Kato, Shigeru Horiguchi, Ryuichi Yoshida, Yuzo Umeda, Soichiro Fushimi, Takahito Yagi, Akihiro Matsukawa & Hiroyuki Okada. (2019) The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Journal of Gastroenterology 54:11, pages 1019-1028.
Crossref
Crossref
Jun-Ying Xu, Wang-Sheng Wang, Jing Zhou, Chao-Ying Liu, Jing-Ling Shi, Pei-Hua Lu & Jun-Li Ding. (2019) The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer. Pancreas 48:7, pages 904-912.
Crossref
Crossref
Ludmila Danilova, Won Jin Ho, Qingfeng Zhu, Teena Vithayathil, Ana De Jesus-Acosta, Nilofer S. Azad, Daniel A. Laheru, Elana J. Fertig, Robert Anders, Elizabeth M. Jaffee & Mark Yarchoan. (2019) Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunology Research 7:6, pages 886-895.
Crossref
Crossref
V. B. Matveev, A. A. Kirichek, V. M. Safronova, N. V. Kokosadze, O. A. Khalmurzaev, B. Sh. Kamolov & L. N. Liubchenko. (2019) The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer. Cancer Urology 15:1, pages 57-65.
Crossref
Crossref
Ying Hu, Wanzhen Chen, Zhanpeng Yan, Jingxia Ma, Fangshi Zhu & Jiege Huo. (2019) Prognostic value of PD-L1 expression in patients with pancreatic cancer. Medicine 98:3, pages e14006.
Crossref
Crossref
Jun Gong, Andrew Hendifar, Richard Tuli, Jeremy Chuang, May Cho, Vincent Chung, Daneng Li & Ravi Salgia. (2018) Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade. Clinical and Translational Medicine 7:1.
Crossref
Crossref
Hui-Ching Wang, Wen-Chun Hung, Li-Tzong Chen & Mei-Ren Pan. (2018) From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. International Journal of Molecular Sciences 19:11, pages 3584.
Crossref
Crossref
Ping Fan, Jinlong Ma & Xin Jin. (2018) Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. Biochemical and Biophysical Research Communications 505:3, pages 830-836.
Crossref
Crossref
Yih Ho, Yan-Fang Chen, Li-Hsuan Wang, Kuang-Yang Hsu, Yu-Tang Chin, Yu-Chen S. H. Yang, Shwu-Huey Wang, Yi-Ru Chen, Ya-Jung Shih, Leroy F. Liu, Kuan Wang, Jacqueline Whang-Peng, Heng-Yuan Tang, Hung-Yun Lin, Hsuan-Liang Liu & Shwu-Jiuan Lin. (2018) Inhibitory Effect of Anoectochilus formosanus Extract on Hyperglycemia-Related PD-L1 Expression and Cancer Proliferation. Frontiers in Pharmacology 9.
Crossref
Crossref
Robert J. Torphy, Yuwen Zhu & Richard D. Schulick. (2018) Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Annals of Gastroenterological Surgery 2:4, pages 274-281.
Crossref
Crossref